$TRIL this what TG Therapeutics paid in 2018 for CD47. There data is not even close to what TRIL has. TG Therapeutics to license the rights to TG-1801, in which case Novimmune will be eligible to receive additional payments contingent on certain clinical, regulatory and commercial milestones, totaling approximately $185MM as well as tiered royalties on net sales.
  • 3
  • 2